Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

This study has been completed.
Novartis Pharmaceuticals
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute Identifier:
First received: June 29, 2011
Last updated: November 24, 2014
Last verified: November 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2014
  Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):